SAR.LSE Sareum Hldgs Plc

Healthcare Pharmaceuticals London Exchange
0.1525 GBX
Close of Nov 3, 2026
11.75 40.00
Market cap
GBX 21.3M
P/E
-
P/B
17.85x
ROE
-553.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Dec 2025.

Is SAR.LSE undervalued?

Graham number

The Graham number of Sareum Hldgs Plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sareum Hldgs Plc fundamental analysis

No fundamental analysis for Sareum Hldgs Plc yet.

Sareum Hldgs Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sareum Hldgs Plc

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-sta…

Full company profile